ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE

Cardboard box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DogStem suspension for injection for dogs

2. STATEMENT OF ACTIVE SUBSTANCES

Each vial contains:
$6.5x10^6$ - $9x10^6$ /ml Equine umbilical cord mesenchymal stem cells

3. PHARMACEUTICAL FORM

Suspension for injection

4. PACKAGE SIZE

1 ml

5. TARGET SPECIES

Dogs

6. INDICATIONS

7. METHOD AND ROUTE OF ADMINISTRATION

For intraarticular use.
Swirl gently before use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNINGS, IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {day/month/year}
Once opened use immediately

11. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated
Do not freeze

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.
To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

EquiCord SL
C/ Loeches 103-D
Alcorcon
Madrid
28925
Spain

16. MARKETING AUTHORISATION NUMBER(S)

Vm 55127/5000

17. MANUFACTURER'S BATCH NUMBER

Batch {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

2 mL vial

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DogStem suspension for injection for dogs

2. QUANTITY OF THE ACTIVE SUBSTANCE

$6.5x10^6$ - $9x10^6$/ml Equine umbilical cord mesenchymal stem cells

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

4. ROUTE OF ADMINISTRATION

Intraarticular

5. WITHDRAWAL PERIOD

6. BATCH NUMBER

Batch {number}

7. EXPIRY DATE

EXP {day/month/year}

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

DogStem suspension for injection for dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder and manufacturer responsible for batch release:

EquiCord SL
C/ Loeches 103-D
Alcorcon
Madrid
28925
Spain

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

DogStem suspension for injection for dogs

3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Each vial contains:
Active Substance: $6.5x10^6$ - $9x10^6$Equine umbilical cord mesenchymal stem cells

Excipient:
Adenosine
Dextran-40
Lactobionate
HEPES N-(2-hydroxyethyl) piperazine-N´-(2-ethanesulfonic acid)
Glutathione
Sodium salts
Chlorine salts
Bicarbonate salts
Phosphate salt
Potassium salts
Glucose
Sucrose
Mannitol
Calcium salts
Magnesium salts
Trolox (6-hydroxyl-2,5,7,8- tetramethylchroman-2-carboxylic acid)
Water for injections.

Suspension for injection.

Cloudy colourless suspension.

4. INDICATION

Improvement in function, reduction of pain and lameness associated with mild to severe osteoarthritis in hip and elbow joints.

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. ADVERSE REACTIONS

Lameness and pain (mild to severe) was reported very commonly within 24 hours after product administration. Lameness and pain with a delayed onset (≤1 week post-treatment) was also observed commonly. Resolution of lameness and pain depended on the severity. Mild lameness and pain resolved completely within a few days without the need for anti-inflammatory treatment. Severe lameness and pain required symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and complete remission took a period of weeks.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system

7. TARGET SPECIES

Dogs.

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Route of administration:
Intraarticular use.

Dosage :
A single intraarticular injection of 1 ml ($6.5x10^6$ - $9x10^6$ equine umbilical cord mesenchymal stem cells) into the affected joint.

Method of administration :
The veterinary product must be administered intraarticularly, only by a veterinary surgeon, taking special precautions to ensure the sterility of the injection process. The product must be handled and injected following sterile techniques and in a clean environment.

Swirl gently before use in order to ensure the contents are well mixed.
Use a 23G needle.
Intraarticular placement should be confirmed by the appearance of synovial fluid in the hub of the needle.
The use of a single dose of systemic NSAIDs is recommended on the day of product administration.

9. ADVICE ON CORRECT ADMINISTRATION

Do not apply simultaneously with other intraarticular veterinary medicinal products.

The product should only be administered by a veterinary surgeon.

Use a 23G needle.
Intraarticular placement should be confirmed by the appearance of synovial fluid in the hub of the needle.

10. WITHDRAWAL PERIOD

Not applicable

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the vial label

12. SPECIAL WARNINGS

Special warnings for each target species:
The veterinary medicinal product has been demonstrated to be efficacious in dogs with mild to severe osteoarthritis in elbow or hip joints diagnosed using a combination of local heat, effusion, joint mobility, joint mobility, pain on palpation, lameness and radiological image. Efficacy data are not available regarding treatment of other joints.

Efficacy of the veterinary medicinal product demonstrated that by day 56 51.4% of dogs treated with the product had achieved more than 7% improvement in functional outcome (measured by Peak Vertical Force (normalised for bodyweight) with associated improvement in lameness, pain on palpation, local heat and effusion and improved quality of life.

The onset of efficacy may be gradual. Clinical improvement may be seen by 4 weeks after treatment, but more likely by 8-12 weeks after treatment.
Reduced pain and increased mobility of the treated joint may last from 3 months to more than a year (in 27.5% of dogs treated with the product in a clinical study; results from an owner questionnaire) There may be improvements in temperament, in playing with other dogs, in stiffness, ability to run and climb stairs.

The efficacy and safety of the veterinary medicinal product were demonstrated in a pivotal field trial after single administration of the veterinary medicinal product and concurrent single systemic administration of an NSAID. According to the benefit-risk assessment of the responsible veterinarian of the individual case a single dose systemic NSAID may be administered on the day of intra-articular injection.

No efficacy and safety data are available regarding the treatment in more than one arthritic joint at the same time.

Special precautions for use in animals:
Correct placement of the needle is crucial to avoid accidental injection into blood vessels and an associated risk of thrombosis.
The safety of the veterinary medicinal product has only been investigated in dogs at least one year old.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
There are only limited data available to support the human safety of this product. In particular, women of childbearing age and people with compromised immune systems should take care to avoid contact with the product. It is recommended to wear impermeable gloves at all times whilst handling and administering the product. Wash any spills off exposed skin, eyes, or mucous membranes immediately.

The product contains Dextran-40, which may cause hypersensitivity (allergic) type reactions in some people. Avoid contact with the product if you know you are sensitised to this substance.

Take care not to accidentally self-administer this product. In case of accidental self-injection, this product can cause pain, local inflammatory reactions and swelling at the site of injection, which may persist for several weeks. Transient fever may also occur. Seek medical advice immediately and provide the package leaflet or label to the physician.

Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interactions
Do not administer simultaneously with any other intraarticular veterinary medicinal product.

Overdose (symptoms, emergency procedures, antidotes):
No data available

Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed in the same syringe with any other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

DD/MM/YYYY

Find more product information by searching for the 'Product Information Database' or 'PID' on www.gov.uk.

15. OTHER INFORMATION

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder



Approved: 07 September 2022